BRIEF-Cocrystal Pharma’s CC-42344 Shows Strong Antiviral Potency Against 2024 H5n1 Avian Influenza Strain

Reuters
29 May
BRIEF-Cocrystal Pharma’s CC-42344 Shows Strong Antiviral Potency Against 2024 H5n1 Avian Influenza Strain

May 29 (Reuters) - Cocrystal Pharma Inc COCP.O:

  • COCRYSTAL PHARMA’S INVESTIGATIONAL DRUG CANDIDATE CC-42344 DEMONSTRATES STRONG ANTIVIRAL POTENCY AGAINST THE 2024 HIGHLY PATHOGENIC H5N1 AVIAN INFLUENZA STRAIN

Source text: ID:nGNX1vmqXg

Further company coverage: COCP.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10